Northwest Biotherapeutics (NBYB) Stock Statistics & Valuation Metrics

Northwest Biotherapeutics has a market cap or net worth of €240.05M. The enterprise value is €374.52M.

Northwest Biotherapeutics has 1,688,074,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Northwest Biotherapeutics’s return on equity (ROE) is 1.29 and return on invested capital (ROIC) is -186.49%.

The current PE Ratio of Northwest Biotherapeutics is ―. Northwest Biotherapeutics’s PEG ratio is 0.14.

In the last 12 months, Northwest Biotherapeutics had revenue of 1.38M and earned -61.48M in profits. Earnings per share was -0.04.

In the last 12 months, operating cash flow was -47.85M and capital expenditures -433.00K, giving a free cash flow of -48.29M billion.

Northwest Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Northwest Biotherapeutics upcoming earnings date is May 16, 2018, After Close (Confirmed).

Northwest Biotherapeutics as a current ratio of 0.06, with Debt / Equity ratio of -168.14%

In the past 12 months, Northwest Biotherapeutics has paid 778.00K in taxes.

Northwest Biotherapeutics EV to EBITDA ratio is -7.92, with an EV/FCF ratio of -8.50.

Northwest Biotherapeutics has €1.79M in cash and marketable securities with €63.99M in debt, giving a net cash position of -€62.21M billion.

Gross margin is -44.89%, with operating margin of -4347.90%, and net profit margin of -4461.32%.

The average price target for Northwest Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―